GYRE (Gyre Therapeutics) Price-to-Tangible-Book : 13.35 (As of May. 11, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Price-to-Tangible-Book?

As of today (2025-05-11), Gyre Therapeutics's share price is $9.53. Gyre Therapeutics's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $0.71. Hence, Gyre Therapeutics's Price to Tangible Book Ratio of today is 13.35.

The historical rank and industry rank for Gyre Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

GYRE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 13.35 Med: 16.95 Max: 16.95
Current: 13.42

During the past 4 years, Gyre Therapeutics's highest Price to Tangible Book Ratio was 16.95. The lowest was 13.35. And the median was 16.95.

GYRE's Price-to-Tangible-Book is ranked worse than
89.43% of 1202 companies
in the Biotechnology industry
Industry Median: 2.595 vs GYRE: 13.42

A closely related ratio is called PB Ratio. As of today, Gyre Therapeutics's share price is $9.53. Gyre Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2024 was $0.73. Hence, Gyre Therapeutics's P/B Ratio of today is 12.98.

Gyre Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Gyre Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Price-to-Tangible-Book Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

16.95

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial						-	27.19	17.39	17.49	16.95

Competitive Comparison of Gyre Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Gyre Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Gyre Therapeutics Price-to-Tangible-Book Calculation

Gyre Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	9.53	/	0.714
	=	13.35

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Gyre Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.